The independent source for health policy research, polling, and news.
461-480 of 705 results
In this episode of KHNâs âWhat the Health?â Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Kimberly Leonard of the Washington Examiner and Alice Ollstein of Politico discuss a flurry of proposals from the Trump administration on prices Medicare pays for drugs and the Affordable Care Act.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you donât have to.
In this episode of KHNâs âWhat the Health?â Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Stephanie Armour of The Wall Street Journal and Joanne Kenen of Politico discuss how protections for people with preexisting conditions have become a top issue in the elections, Trump administration efforts to make prescription drug prices more public and the start of Medicareâs annual open-enrollment period. Plus, Rovner interviews California Attorney General Xavier Becerra.
Drug pricing is a top issue in the run-up to the midterm elections.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you donât have to.
In this episode of KHNâs âWhat the Health?â Mary Agnes Carey of Kaiser Health News, Rebecca Adams of CQ Roll Call, Anna Edney of Bloomberg News and Julie Appleby of Kaiser Health News discuss the Trump administrationâs announcement that average premium prices are falling on the Obamacare marketplaces, the effort by Senate Democrats to reverse rules on short-term health insurance and the focus on protections for people with preexisting conditions in the run-up to midterm elections.
Congress approved two bills last month that prohibit provisions keeping pharmacists from telling patients when they can save money by paying the cash price instead of the price negotiated by their insurance plan.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you donât have to.
Health insurers and pharmacy benefit managers are exploring how two legal provisions â which have been on the books for decades â could bring down the price tags of certain prescription medications.Â
In this episode of KHNâs âWhat the Health?â Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Margot Sanger-Katz of The New York Times and Kimberly Leonard of the Washington Examiner discuss final action on bills in Congress to address the opioid epidemic and fund federal health agencies. They also look at new efforts by the Food and Drug Administration to crack down on teen nicotine use.
Pharmaceutical companies like Purdue Pharma, maker of OxyContin, often win patents for incremental changes with debatable value. Now thereâs a twist involving an opioid treatment.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you donât have to.
In this episode of KHNâs âWhat the Health?â Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Anna Edney of Bloomberg News and Alice Ollstein of Politico talk about how health issues will play in midterm elections, the Trump administrationâs move that could penalize legal immigrants who use government aid programs, and other topics. Due to technical difficulties, the original discussion taped Sept. 27 at the 2018 Texas Tribune Festival could not be broadcast, so the panelists reconvened from Austin and Washington on Sept. 28.
The protection is a win for people who get their needed, legitimate drugs from overseas.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you donât have to.
Medicaid drug spending doubled in five years in Massachusetts. The state wanted to exclude expensive drugs that weren't proven to work better than existing alternatives from its Medicaid plan, but the federal government blocked the effort.
Federal officials are allowing the private insurance plans to use âstep therapyâ for drugs administered by doctors. In step therapy, patients must first use cheaper drugs to see if they work before receiving more expensive options.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you donât have to.
As HHS decided to cut $1.6 billion in drug payments to hospitals, it weighed thousands of comments generated by a pharmaceutical-funded advocacy group.
© 2026 51ÊÓÆ”